Why not approach the generics with a smart compromise: Give Amarin the US market for a few years to build it up, then come in when it's worth the effort.
What are the generics gaining by launching a drug into a market still in it's infancy? Seems like they won and we lost, but logic is still logic if both sides face reality.
A settlement would benefit both sides greatly in the long term, but does JT have what it takes to negotiate this kind of solution? I would posit that the share price would double if he secured the US market for 5 years, and generics would have much higher sales than they will get now.
JMO but man it seems to make a lot of sense.
News 
Market Data 
Discover 
